HAVCR2 and neoplasm: HMGB1 has been reported as a ligand for TIM-3 expressed by tumor-infiltrating DCs [23], and it has recently been suggested that the binding of HMGB1 to TIM-3 on regulatory CD8+ T cells can inhibit the expansion of effector T cells [24,25].